Sheaff Brock Investment Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-97	Closed	-$46K	–	526
2018 Q3	$46K	Buy	97 +17	+21%	+$7.29K	﹤0.01%	515
2018 Q2	$36K	Hold	80	–	–	﹤0.01%	531
2018 Q1	$47K	Hold	80	–	–	﹤0.01%	534
2017 Q4	$50K	Hold	80	–	–	0.01%	516
2017 Q3	$74K	Hold	80	–	–	0.01%	547
2017 Q2	$75K	Sell	80 -7	-8%	-$6.86K	0.01%	581
2017 Q1	$82K	Buy	87 +7	+9%	+$6.52K	0.01%	568
2016 Q4	$64K	Hold	80	–	–	0.01%	585
2016 Q3	$67K	Hold	80	–	–	0.01%	528
2016 Q2	$66K	Sell	80 -7	-8%	-$7.62K	0.01%	561
2016 Q1	$97K	Sell	87 -1	-1%	-$1.02K	0.01%	558
2015 Q4	$109K	Buy	+88	New	+$146K	0.01%	578

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sheaff Brock Investment Advisors's TCRT Position: Q4 2018 in Review

Sheaff Brock Investment Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 97 shares — an estimated $46K sold.

Sheaff Brock Investment Advisors first reported a position in TCRT in Q4 2015 and held it in 12 quarters. The position peaked at $109K in Q4 2015. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

Sheaff Brock Investment Advisors reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 97 Alaunos Therapeutics shares in Q4 2018, an estimated $46K.
Sheaff Brock Investment Advisors first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 12 quarters.
Sheaff Brock Investment Advisors's Alaunos Therapeutics position peaked at $109K in Q4 2015.
137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2018, filed 28 Jan 2019.